Workflow
WuXi AppTec(603259)
icon
Search documents
29.96亿元资金今日流入医药生物股
Market Overview - The Shanghai Composite Index rose by 0.33% on July 29, with 16 out of 28 sectors experiencing gains, led by the communication and steel industries, which increased by 3.29% and 2.59% respectively [1] - The pharmaceutical and biological industry ranked third in terms of daily gains, rising by 2.06% [1] - Conversely, the agriculture, forestry, animal husbandry, and fishery sectors, along with the banking sector, saw declines of 1.36% and 1.19% respectively [1] Capital Flow Analysis - The net outflow of capital from the two markets reached 35.637 billion yuan, with only four sectors experiencing net inflows [1] - The pharmaceutical and biological sector led the net inflow with 2.996 billion yuan, followed by the steel sector with a net inflow of 419 million yuan [1] - The non-ferrous metals sector had the highest net outflow, totaling 4.434 billion yuan, followed by the machinery equipment sector with a net outflow of 3.792 billion yuan [1] Pharmaceutical and Biological Sector Performance - The pharmaceutical and biological sector saw a net inflow of 2.996 billion yuan, with 341 out of 474 stocks in the sector rising, including 11 stocks hitting the daily limit [2] - The top three stocks with the highest net inflow were: - Zhongsheng Pharmaceutical with a net inflow of 303 million yuan and a daily increase of 9.98% - Zhifei Biological with a net inflow of 256 million yuan and a daily increase of 6.50% - Jiuzhou Pharmaceutical with a net inflow of 250 million yuan and a daily increase of 10.01% [2] - Seven stocks in the sector experienced net outflows exceeding 100 million yuan, with the largest outflows from: - Hengrui Medicine at 352 million yuan - Saili Medical at 187 million yuan - WuXi AppTec at 173 million yuan [2][4] Capital Inflow and Outflow Rankings - The top stocks by capital inflow in the pharmaceutical sector included: - Zhongsheng Pharmaceutical: +9.98%, turnover rate 15.34%, inflow 302.59 million yuan - Zhifei Biological: +6.50%, turnover rate 9.19%, inflow 255.84 million yuan - Jiuzhou Pharmaceutical: +10.01%, turnover rate 12.54%, inflow 249.88 million yuan [2] - The top stocks by capital outflow included: - Hengrui Medicine: +2.84%, turnover rate 2.64%, outflow -352.45 million yuan - Saili Medical: -4.62%, turnover rate 28.21%, outflow -186.81 million yuan - WuXi AppTec: +7.72%, turnover rate 3.78%, outflow -173.05 million yuan [4]
港股收盘 | 恒指收跌0.15% 医药股再度强势 药明康德绩后大涨11%领跑蓝筹
Zhi Tong Cai Jing· 2025-07-29 08:51
港股今日低开低走,三大指数盘中均一度跌超1%,尾盘跌幅则有所收窄。截止收盘,恒生指数跌0.15% 或37.68点,报25524.45点,全日成交额为2670.1亿港元;恒生国企指数跌0.34%,报9145.92点;恒生科 技指数跌0.35%,报5644.38点。 申万宏源认为,近期国内中长期改革政策加速兑现,供给侧政策(以反内卷为代表)和需求侧政策(以 生育支持政策为代表)相互配合,将有效改善宏观经济和企业盈利预期,显著提振中国资本市场的长期 信心。继续看好港股是潜在牛市中领涨市场,"牛市氛围"强化后,投资者在港股进行行业轮动会更加积 极。 蓝筹股表现 药明康德(603259)(02359)领涨蓝筹。截至收盘,涨11.25%,报111.7港元,成交额30.23亿港元,贡献 恒指6.33点。药明康德发布2025年上半年业绩,公司实现收入207.99亿元(人民币,下同),同比增加 20.6%;母公司持有者的应占净溢利82.87亿元,同比增加95.5%。报告期内,公司持续经营收入204.1亿 元,其中来自美国客户收入140.3亿元,同比增长38.4%。此外,公司还宣布上调全年业绩指引。 其他蓝筹股方面,石药集团(0 ...
港股收盘(07.29) | 恒指收跌0.15% 医药股再度强势 药明康德(02359)绩后大涨11%领跑蓝筹
智通财经网· 2025-07-29 08:49
Core Viewpoint - The Hong Kong stock market experienced a decline, with the Hang Seng Index closing down 0.15% at 25,524.45 points, while the overall market sentiment remains optimistic due to accelerating domestic reform policies that are expected to improve macroeconomic conditions and corporate earnings expectations [1] Group 1: Blue Chip Performance - WuXi AppTec (02359) led the blue-chip stocks, rising 11.25% to HKD 111.7, contributing 6.33 points to the Hang Seng Index, with a reported revenue of RMB 20.799 billion for the first half of 2025, a year-on-year increase of 20.6% [2][4] - Other blue-chip stocks included CSPC Pharmaceutical Group (01093) up 8.46% and Zhongsheng Group (00881) up 6.23%, while Xiaomi (01810) and Hong Kong Exchanges and Clearing (00388) saw declines of 2.64% and 1.91%, respectively [2] Group 2: Sector Highlights - The biopharmaceutical sector saw a resurgence, with WuXi AppTec's strong interim results and upgraded annual guidance driving significant gains in the CRO sector [3][4] - The photovoltaic sector also showed recovery, with GCL-Poly Energy (03800) rising 7.69%, supported by government policies aimed at improving industry standards and eliminating excess capacity [6] Group 3: Childcare Policy Impact - The newly announced national childcare subsidy policy, effective from January 1, 2025, will provide annual subsidies of RMB 3,600 for families with children under three years old, which is expected to boost consumer spending in the maternal and infant sectors [5][6] Group 4: Notable Stock Movements - Changfei Optical Fiber (06869) saw a significant increase of 12.55%, attributed to advancements in various technology sectors [7] - Shanghai Fudan (01385) rose 9.87% following a technology service contract with Fudan University to develop advanced FPGA technology [8] - Goodbaby International (01086) issued a profit warning, expecting a decline in net profit by 40% to 50% despite slight revenue growth [11]
药明康德:将回购股份价格上限由不超过90.72元/股(含)调整为不超过人民币114.15元/股,回购方案其他内容不变
Ge Long Hui· 2025-07-29 08:49
格隆汇7月29日|药明康德(603259):将回购股份价格上限由不超过90.72元/股(含)调整为不超过人民币 114.15元/股,回购方案其他内容不变。 (责任编辑:宋政 HN002) 【免责声明】本文仅代表作者本人观点,与和讯网无关。和讯网站对文中陈述、观点判断保持中立,不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考,并请自行承担全部责任。邮箱: news_center@staff.hexun.com ...
药明康德7月大涨超四成:外资投行集体唱多 CXO行业或已迎来拐点
药明康德H股7月以来累计上涨逾42%,年内涨幅超103%,表现更胜A股。 股价大涨背后是公司坚实的业绩表现——药明康德7月28日晚间发布的2025年半年报显示,上半年公司 营收达208亿元,同比增长20.64%;净利润达85.6亿元,同比增长101.92%,创上市以来最佳半年表现; 扣非净利55.82亿元,同比增长26.47%;毛利率提升至44.45%,亦创上市以来半年报数据最高纪录。 靓丽的半年报发布后,多家外资投行就药明康德发布研报上调公司目标价。 转自:新华财经 新华财经上海7月29日电(林郑宏)7月29日,A股三大股指延续涨势,沪指收盘站上3600点整数关口, 收盘点位创年内新高;深成指涨0.64%,创业板指大涨1.86%,自去年11月13日后收盘点位首次突破 2400点整数关口。 医药股成为推动创业板指上涨的主要动力,CXO、减肥药、创新药等概念板块领涨两市,其中CXO板 块涨幅居首。成交额超过10亿元的8只行业主题类ETF中,易方达沪深300医药ETF(512010)上涨 2.68%,成交13.63亿元,位列第4;华宝中证医疗ETF(512170)上涨2.45%,成交11.52亿元,位列第 7。 ...
药明康德(603259) - 关于调整回购股份价格上限的公告
2025-07-29 08:47
证券代码:603259 证券简称:药明康德 公告编号:临 2025-052 无锡药明康德新药开发股份有限公司 1 年 6 月 25 日披露的《关于 2025 年第一次以集中竞价交易方式回购 A 股股份的 回购报告书》(公告编号:临 2025-042)。 二、回购股份的进展情况 截至 2025 年 7 月 28 日,公司在本次回购方案下累计通过集中竞价交易方 式回购 A 股股份 6,514,425 股,占公司总股本的 0.23%,回购最高价格为人民币 90.70 元/股,回购最低价格人民币 65.53 元/股,回购价格均价人民币 76.34 元/ 股,使用资金总额人民币 497,297,934.64 元(不含交易费用)。 关于调整回购股份价格上限的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 无锡药明康德新药开发股份有限公司(以下简称"公司")于 2025 年 7 月 29 日召开第三届董事会第二十三次会议,审议通过了《关于调整回购股份价 格上限的议案》,公司拟将 2025 年第一次以集中竞价交易方式回购 ...
港股收评:午后回升,恒指跌0.15%,创新药涨幅抢眼,下跌之际南下资金净买入港股超100亿港元!药明康德涨超11%,小米跌2.6%
Ge Long Hui· 2025-07-29 08:42
Market Overview - The Hang Seng Index closed at 25,524.45, down by 0.15%, while the Hang Seng China Enterprises Index fell by 0.34% to 9,145.92. The Hang Seng Tech Index decreased by 0.35% to 5,644.38, with intraday declines reaching 1.2% for the first two indices and a significant drop of 2% for the tech index [1] - Despite the index adjustments, southbound capital saw a substantial net purchase of Hong Kong stocks exceeding 10 billion HKD [1] Stock Performance - Notable gainers in the biopharmaceutical sector included WuXi AppTec (up 11.25%), with other companies like CSPC Pharmaceutical and Green Leaf Pharmaceutical also showing strong performance, rising over 8% [3] - The top-performing stocks included WuXi Biologics-B (up 33.33%), Chuangsheng Group-B (up 17.06%), and Dongyao Pharmaceutical-B (up 15.06%) [2] Sector Trends - Large tech stocks showed a narrowing of losses in the afternoon, with Alibaba slightly turning positive, while Tencent, JD.com, Meituan, and Kuaishou experienced declines within 1%. Xiaomi fell by 2.6%, and Baidu dropped nearly 2% [3] - The "anti-involution" sectors, including steel and photovoltaic stocks, saw a rebound, while sectors like banking, catering, and robotics generally declined [3]
药明康德:拟将回购股份价格上限调整为不超114.15元/股
人民财讯7月29日电,药明康德(603259)7月29日晚间公告,拟将2025年第一次以集中竞价交易方式回 购A股股份的回购股份价格上限由不超过90.72元/股(含)调整为不超过114.15元/股,本次回购方案的 其他内容不变。 ...
688585,巨震!
"10倍股"上纬新材(688585)今天盘中股价再创历史新高,但走势波动较大。该股今天上涨6.19%,今年以来累计涨1169%。 上午,上纬新材一度涨近18%,午后股价缓慢回落,13:42左右,股价突然直线跳水翻绿,后又大幅拉升,一度涨超15%,临近尾盘,股价再度跳水。今 天,上纬新材成交额超21亿元。 算力和创新药板块走强 近期,算力、创新药及其上游的CXO板块持续走强。今天,这两大板块再度大涨。 CRO板块今天领涨,睿智医药、药石科技等个股大涨。两大龙头股药明康德、恒瑞医药分别上涨7.72%、2.84%。 7月29日,A股三大指数全线飘红,创业板指站上2400点。 截至收盘,上证指数上涨0.33%,深证成指上涨0.64%,创业板指上涨1.86%,报2406.59点。全市场成交额约1.83万亿元。 上纬新材巨震 一是各板块的龙头股持续走强,每天都有不少龙头股刷新历史新高。今天,新易盛、中际旭创、生益科技、胜宏科技、仕佳光子、沪电股份、工业富联、 苑东生物、益方生物、芯碁微装、电气风电等个股盘中股价创历史新高。 二是市场更加聚焦大市值和中市值的龙头股。 | | | 874.62 4.00% | | | | - ...
688585,巨震
截至收盘,上证指数上涨0.33%,深证成指上涨0.64%,创业板指上涨1.86%,报2406.59点。全市场成交额约1.83万亿元。 上纬新材巨震 "10倍股"上纬新材(688585)今天盘中股价再创历史新高,但走势波动较大。该股今天上涨6.19%,今年以来累计涨1169%。 7月29日,A股三大指数全线飘红,创业板指站上2400点。 上午,上纬新材一度涨近18%,午后股价缓慢回落,13:42左右,股价突然直线跳水翻绿,后又大幅拉升,一度涨超15%,临近尾盘,股价再度跳水。今 天,上纬新材成交额超21亿元。 算力和创新药板块走强 近期,算力、创新药及其上游的CXO板块持续走强。今天,这两大板块再度大涨。 CRO板块今天领涨,睿智医药、药石科技等个股大涨。两大龙头股药明康德、恒瑞医药分别上涨7.72%、2.84%。 | | | 874.62 4.00% | | | | --- | --- | --- | --- | --- | | 成分股 | 基金 | 资金 | 板块分析 | 新闻 | | ●展开分析 | | 最新 | 涨幅 ◆ | 流通市值 | | 睿智医药 | | 13.61 | 20.02% | 67.7 ...